Navigation Links
ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011
Date:3/2/2011

SHANGHAI, March 2, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release its unaudited financial results for the fourth quarter and full year 2010 ended December 31, 2010 on March 15, 2011. Management will host a conference call to discuss the results at 8:00am New York Time on March 15, 2011 (8:00pm Beijing time on March 15, 2011).

Conference Call

Mr. Michael Hui, founder and Chief Executive Officer, Mr. Kevin Chen, President and Chief Operating Officer, and William Dai, Chief Financial Officer, will discuss the results and take questions following the prepared remarks.

The dial-in details for the live conference call are as follows:- U.S. Toll Free Number:

1.800.299.9630- International dial-in number:

+ 1.617.786.2904- China Toll Free Number:

10 800 152 1490 (North)10 800 852 1490(South)- Hong Kong Toll Free Number:800 963 844Passcode:

SHPA live webcast of the conference call will be available on the investor relations section of the Company's website at: http://www.shangpharma.com.

A telephone replay of the call will be available for seven days from March 15, 2011 to March 22, 2011. The dial-in details for the replay are as follows:

- U.S. Toll Free Number:

1-888-286-8010- International dial-in number:+1-617-801-6888Passcode:

85666096About ShangPharma Corp.ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

For further information, contact:ShangPharma CorporationLan Xie, VP of Finance and OperationsE-mail: IR@shangpharma.comChristensenIn New YorkKimberly Minarovich,Phone: +1 917-533-3268E-mail: kminarovich@christensenir.comIn Hong KongTip FlemingPhone: +852-9212-0684Email: tfleming@ChristensenIR.com  
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dynamic Ventures Corp. Reaches An Agreement in Principle with NOVA Home Loans
2. Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain
3. Mr Claude Poulin nominated as President and CEO of Neuro-Biotech Corp.
4. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
5. Norgen Biotek Corp. Launches a Novel kit to Collect, Concentrate, Preserve and Isolate DNA, RNA, microRNA and proteins from Urine Specimens
6. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
7. IGEN Networks Corp. obtains Blue Sky Statutory Compliance in 38 States with Approval of Standard & Poors
8. NephRx Corp. Receives Orphan Drug Designation for NX001 for Prevention of Delayed Kidney Graft Function
9. FutureFuel Corp. Declares Dividend
10. CRH Medical Corp. Joins OTCQX
11. IGEN Networks Corp. announces new Board member and the cancellation of three million shares for return to treasury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Cleveleys, UK (PRWEB) , ... ... ... results presented by surgeons at the 2016 annual meeting of the North ... beneficial clinical outcomes, for patients in the majority of cases, when PEEK-OPTIMA™ ...
(Date:1/17/2017)... 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... a global Phase 2b induction study in ulcerative ... alpha4beta7 integrin. The aim of this randomized, double-blind, ... safety/tolerability and efficacy of PTG-100 in approximately 240 ... active disease. "We are very ...
(Date:1/16/2017)... 16, 2017  Eurofins Genomics today announced the expansion ... customers to receive their primers in a shorter turnaround ... quality found with other providers. Express oligos are available ... at no additional fee. Researchers use ... including DNA sequencing, genotyping, site-directed mutagenesis, and cloning. Often, ...
(Date:1/13/2017)... ... January 13, 2017 , ... Two ... organic compound called fulvic acid that farms, greenhouses and hydroponics operations use to ... are among the fastest growing segments of customers using this high grade fulvic ...
Breaking Biology Technology:
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell , ... technology, and STMicroelectronics (NYSE: STM), a global ... electronics applications, announced today the launch of a ... biometric wearables that includes ST,s compact SensorTile ... Benchmark™ biometric sensor system. Together, SensorTile and ...
(Date:12/15/2016)... , December 15, 2016 Arvato ... an agreement with NuData Security, an award-winning international ... will enable clients to focus on good customer experience, balancing ... regulation. ... In order to provide a one-stop fraud prevention suite, Arvato ...
(Date:12/15/2016)... 2016 "Increase in mobile transactions is driving ... biometrics market is expected to grow from USD 4.03 ... at a CAGR of 29.3% between 2016 and 2022. ... growing demand for smart devices, government initiatives, and increasing ... component is expected to grow at a high rate ...
Breaking Biology News(10 mins):